Naloxone administration does not affect gonadotropin secretion in agonadal men either basally or during testosterone treatment.
Naloxone administration has no effect on plasma gonadotropin levels of agonadal men. The present study was designed to evaluate whether testosterone replacement therapy could restore LH responsiveness to naloxone in such men. We measured plasma LH and FSH levels at 15-min intervals during naloxone infusion (8 mg in 1 min followed by 12 mg in 3 h) and for the following 3 h in a group of agonadal men both before and after at least 2 months of three different schedules of testosterone replacement therapy: 1) testosterone undecanoate, 40 mg three times a day by mouth; 2) testosterone enanthate 200 mg im every 2 weeks; and 3) testosterone enanthate 100 mg im once a week. Mean plasma gonadotropin levels as well as LH pulse frequency did not vary during naloxone infusion vs. placebo either basally or during each testosterone regimen. These results suggest that long term testosterone therapy does not affect the altered opioid modulation of gonadotropin secretion which is present in agonadal men.
D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D009919:Orchiectomy; D013737:Testis / Q000002:abnormalities*; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*
D006065:Gonadotropins, Pituitary; D009270:Naloxone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone